Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
- Conditions
- Early-stage Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Renske Altena
- Target Recruit Count
- 6
- Registration Number
- NCT03894007
- Locations
- 🇸🇪
Sahlgrenska universitetssjukhuset, Göteborg, Sweden
🇸🇪Skånes universitetssjukhus, Malmö, Sweden
🇸🇪Länssjukhuset Sundsvall, Sundsvall, Sweden
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES
- Conditions
- POMES SyndromeRelapsed and Refractory POMES Syndrome
- Interventions
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03879382
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT03876886
- Locations
- 🇨🇳
National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic Prostate CarcinomaCastration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytesDrug: CyclophosphamideDrug: FludarabineDrug: Fludarabine Phosphate
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 14
- Registration Number
- NCT03873805
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
- Conditions
- Diffuse Large B-Cell LymphomaBurkitt LymphomaKSHV-associated Multicentric Castleman Disease
- Interventions
- Biological: Rituximab and Hyaluronidase HumanDrug: CyclophosphamideDrug: VincristineDrug: MethotrexateDrug: DoxorubicinBiological: RituximabDrug: Doxorubicin HydrochlorideDrug: PrednisoneDrug: Etoposide
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT03864419
- Locations
- 🇺🇬
UCI-Fred Hutch Cancer Centre, Kampala, Uganda
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
- Conditions
- Solid TumorsAdvanced Triple Negative Breast CancerAdvanced Hormone Receptor Positive/Endocrine Refractory Breast CancerAdvanced Metastatic Castration-Resistant Prostate CancerAdvanced Platinum-Resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03861403
- Locations
- 🇺🇸
Horizon Oncology Research, Lafayette, Indiana, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia
- Interventions
- Drug: IsatuximabDrug: Dexamethasone or equivalentDrug: FludarabineDrug: CytarabineDrug: Liposomal daunorubicinDrug: Daunorubicin (nonliposomal)Drug: IdarubicinDrug: Filgrastim or equivalentDrug: MitoxantroneDrug: DoxorubicinDrug: VincristineDrug: Pegaspargase (PEG) AsparaginaseDrug: CyclophosphamideDrug: EtoposideDrug: MethotrexateDrug: L - AsparginaseDrug: HydroxyureaDrug: L - Asparaginase (Erwinase)
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 67
- Registration Number
- NCT03860844
- Locations
- 🇺🇸
Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States
🇲🇽Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico
🇧🇷Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil
'ADVANCE' (A Pilot Trial)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT03858322
- Locations
- 🇺🇸
Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) at Milford Regional Medical Center, Milford, Massachusetts, United States
🇺🇸Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States
🇺🇸Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in Clinical Affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
- Conditions
- Acute Myeloid Leukemia in RemissionMyelodysplastic SyndromesChronic Myeloid Leukemia in RemissionMyeloproliferative SyndromeMyeloproliferative DisorderAcute Lymphoid Leukemia in RemissionMultiple MyelomaChronic Lymphoid LeukemiaNon Hodgkin LymphomaHodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- University of Liege
- Target Recruit Count
- 114
- Registration Number
- NCT03852407
- Locations
- 🇧🇪
CHU UCL Namur Godinne, Yvoir, Belgium
🇧🇪UZ Gent, Gent, Belgium
🇧🇪UCL St Luc, Brussels, Belgium
Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma
- Conditions
- Angioimmunoblastic T-cell Lymphoma
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT03853044
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.